Camrelizumab in Combination with Apatinib in Patients with Advanced Hepatocellular Carcinoma (RESCUE): A Nonrandomized, Open-label, Phase II Trial

Jianming Xu(Chinese PLA General Hospital), Quanren Wang(Jiangsu Hengrui Medicine (China)), Kuansheng Ma(Army Medical University), Tao Yin(Rutgers, The State University of New Jersey), Jian Wu(Sun Yat-sen University), Xinmin Zhou(Air Force Medical University), Zhenggang Ren(Ministry of Education of the People's Republic of China), Li Xu(Jiangxi University of Traditional Chinese Medicine), Shuni Wang(Jiangsu Hengrui Medicine (China)), Xianhai Mao(Hunan Provincial People's Hospital), Jianping Xiong(Nanchang University), Shanzhi Gu(Central South University), Yanqiao Zhang(Harbin Medical University), Xiao Zhang(Henan Academy of Sciences), Xi Chen(Purdue University West Lafayette), Yun Zhang(Harbin Medical University), Zhiming Wang(Guangzhou University of Chinese Medicine), Jie Shen(Xinjiang Medical University), Kangsheng Gu(Anhui Medical University), Jingfeng Liu(Fujian Medical University), Le‐Qun Li(Shanghai Sixth People's Hospital), Zujiang Yu(First Affiliated Hospital of Zhengzhou University), Zhanyu Pan(Tianjin Medical University Cancer Institute and Hospital), Guoliang Shao(Zhejiang Cancer Hospital), Jiayin Yang(Saudi Center for Organ Transplantation), Lihua Wu(First Affiliated Hospital Zhejiang University), Ling Zhang(Fujian Medical University), Guowen Yin(Jiangsu Cancer Hospital), Enxiao Li(First Affiliated Hospital of Xi'an Jiaotong University)
Clinical Cancer Research
October 21, 2020
10.1158/1078-0432.ccr-20-2571
Cited by 576

Related Papers

Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial
|The Lancet|2012|1.4k
Brivanib Versus Sorafenib As First-Line Therapy in Patients With Unresectable, Advanced Hepatocellular Carcinoma: Results From the Randomized Phase III BRISK-FL Study
|Journal of Clinical Oncology|2013|775
Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial
|The Lancet|2023|701
The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer
|Nature|2021|687
<p>Umbilical Cord-Derived Mesenchymal Stem Cell-Derived Exosomes Combined Pluronic F127 Hydrogel Promote Chronic Diabetic Wound Healing and Complete Skin Regeneration</p>
|International Journal of Nanomedicine|2020|521